Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhC1INH for Early AMR in Renal Transplant
NCT01035593Phase 2Withdrawn
- Sponsor
- Pharming Group
- Start
- Dec 2010
- Primary completion
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in antibody mediated rejection (AMR) comparing Standard of Care (PP + IVIG) with PP + IVIG + rhC1INH (2 arms). Primary endpoint: Renal allograft survival 6 months following treatment for AMR. Planned start Dec 2010; status: withdrawn.
02
Drugs
conestat alfa
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01035593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035593.